CTLA4 and cancer: By targeting immune‐suppressive checkpoint molecules (e.g., PD1, PD‐L1, and CTLA‐4), immunotherapy rescued patients’ immune system and prevented cancer cells from evading the immune surveillance, and thus exerted a consistent antitumor efficacy for heterogenic patients.53